L-4F
Apolipoprotein A-I mimetic peptide L-4F
18 Amino Acids · MW: ~2300 Da
Amino Acids
18
Molecular Weight
~2300 Da
Half-life
Short; hours in free form
Research Score
4.5
Studies
78
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is L-4F?
L-4F is a synthetic apoA-I mimetic peptide studied for improving HDL function and reducing atherogenic lipids. It has been investigated as an anti-atherosclerotic research peptide that can help neutralize oxidized phospholipids and support cholesterol efflux.
Key Benefits & Mechanisms
improves HDL function
promotes cholesterol efflux
reduces oxidized LDL burden
may slow plaque formation
Research Summary
Preclinical studies suggest L-4F can improve HDL quality rather than just HDL quantity, which is relevant to reverse cholesterol transport. Animal and ex vivo work also support anti-inflammatory and plaque-stabilizing effects in atherosclerosis models.
Related Peptides
Carperitide
Recombinant human atrial natriuretic peptide (α-hANP)
Recombinant human atrial natriuretic peptide used mainly in acute heart failure and perioperative volume overload. It promotes natriuresis, vasodilation, and suppression of RAAS signaling to lower preload and afterload.
CardiovascularNesiritide
Recombinant human B-type natriuretic peptide (BNP-32)
Synthetic BNP used to counteract fluid overload and elevated cardiac filling pressures. It increases cyclic GMP, causing venous and arterial vasodilation plus natriuresis.
CardiovascularUlaritide
Synthetic human urodilatin
Urodilatin is a renal natriuretic peptide derived from the proANP precursor and studied as an IV heart-failure therapy. It produces strong natriuresis and vasodilation with a relatively rapid onset.
CardiovascularCenderitide
CD-NP chimeric natriuretic peptide
Cenderitide is a designer natriuretic peptide combining features of CNP and dendroaspis natriuretic peptide. It was engineered to provide balanced natriuretic and vasodilatory activity with potential renal-sparing effects.
Cardiovascular